FMT for MDRO Colonization After Infection in Renal Transplant Recipients (PREMIX)
Infection Due to Resistant Organism
About this trial
This is an interventional treatment trial for Infection Due to Resistant Organism focused on measuring Carbapenem-resistant Enterobacteriaceae (CRE), Vancomycin-resistant Enterococcus (VRE), Multidrug Resistant Organism (MDRO), Fecal Microbiota Transplant (FMT), Renal Transplant, Colonization, Infection, Antibiotic Resistance, Resistome, Multidrug Resistant (MDR) Pseudomonas
Eligibility Criteria
Inclusion Criteria:
- Ability to understand and willingness to sign a written informed consent document.
- Ability and willingness to comply with study protocol requirements and receive an enema.
- History of MDRO infection with at least one of the following target MDROs: CRE, VRE, ESBL, or MDR Pseudomonas.
- Prior receipt of a renal transplant.
- If applicable, willingness to discontinue probiotics or other microbiota restoration therapies during screening at least seven days prior to study Day 1.
- The effects of FMT on the developing human fetus are unknown. For this reason, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
- Negative blood or urine human chorionic gonadotropin (hCG) testing on the day of FMT for WOCBP with documentation of negative test result.
- Negative baseline Human Immunodeficiency Virus (HIV) test.
Known serology CMV status confirmed by Medical History (if positive). If no mention of positivity in medical records, serology is tested within 30 days of enrollment for:
- Cytomegalovirus (CMV) by polymerase chain reaction (PCR)
- Cytomegalovirus (CMV), serology Immunoglobulin G (IgG)
Exclusion Criteria:
- Female participants who are pregnant, breastfeeding, lactating, or planning a pregnancy during study duration (through 4 weeks after the last dose of investigational product).
Prior gastrointestinal surgery or intervention:
- Ileostomy (in the last 3 months)
- Colostomy (in the last 3 months)
- Gastric or colon resection (in the last 3 months)
- Bariatric surgery (any prior history)
- Total colectomy (any prior history)
Any of the following gastrointestinal conditions:
- Irritable Bowel Syndrome (IBS) with diarrhea in the last 12 months
- Crohn's disease
- Ulcerative Colitis
- Celiac disease
- Untreated in-situ colorectal cancer
- Microscopic colitis
- Toxic megacolon or ileus
- Tube feeding (current or planned)
- Known positive stool studies or cultures in the last 30 days for: Ova or parasites, Salmonella, Shigella, Campylobacter
- Other enteropathogens - defined as any positive result other than C. difficile on the Biofire FilmArray gastrointestinal panel, (Campylobacter, Plesiomonas, Salmonella, Vibrio, Yersinia, Enteroaggregative Escherichia coli (EAEC), Enteropathogenic Escherichia coli (EPEC), Enterotoxigenic Escherichia coli (ETEC), Shigella, Cryptosporidium, Cyclospora, Entamoeba, Giardia, Adenovirus, Astrovirus, Norovirus, Rotavirus, Sapovirus).
Known uncontrolled intercurrent illness(es) such as, but not limited to:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Acute coronary syndrome
- Cardiac arrhythmia
- Any other intercurrent acute illness that in the opinion of the investigator will preclude subject from entering the study
- On systemic antibiotics for any reason other than recent MDRO infection. If a potential participant is taking antibiotics for treatment (not prophylaxis) of MDRO infection, then the participant must complete the planned antibiotic course by study Day -2.
Compromised immune system other than transplant immunosuppression:
- HIV-positive as identified by one of the following: Positive HIV test, prior diagnosis of HIV, or active or history of administration of antiretroviral therapy (ART) other than for pre-exposure prophylaxis or post-exposure prophylaxis.
- Known Absolute Neutrophil (ANC) <1000 neutrophils per cubic millimeter (mm^3) in the last 3 months
- Active malignancy requiring intensive induction chemotherapy, radiotherapy, or biologic treatment either concurrently or in the last 2 months
- Acute leukemia
- History of hematopoietic cell transplantation, either allogeneic or autologous in the last 3 years
- History of solid organ transplant rejection in the last 6 months
- Significant food allergy to foods that are part of the stool donor participant's diet.
- Life expectancy is 24 weeks or less.
Any condition that, in the opinion of the investigator, might interfere with study objectives or limit compliance with study requirements, including but not limited to:
- Known active intravenous drug or alcohol abuse
- Psychiatric illness
- Social situation
Participated in an investigational study that also meets one of the following criteria:
- Received an interventional agent (drug, device, or procedure) in the last 28 days
- Enrollment on this study or any other interventional study for MDROs
Sites / Locations
- Emory University Hospital
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Control arm
Fecal Microbiota Transplant (FMT)
The control arm will participate in the bowel preparation and stool or perirectal swab sampling but will not receive Fecal Microbiota Transplant (FMT) nor will they be fasting during their first study cycle (Cycle 0). Participants testing positive for a multi-drug resistant organism at the of Cycle 0 will be eligible to receive microbiota restoration transplant (MRT) for up to two cycles, as necessary (Cycles 1 and 2).
The experimental arm will participate in the bowel preparation, stool or perirectal swab sampling, and will receive Fecal Microbiota Transplant (FMT) using Allogeneic Human Stool in Glycerol 10% (AHSG) on Day 1 of each cycle (Cycles 1 and 2).